Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decreased gene and protein expression levels of ARID1A are related to the occurrence and development of endometriosis-associated ovarian cancer, especially OCCC.
|
29135119 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fukumoto and colleagues present a promising example of this approach for the treatment of ovarian cancer with inactivating ARID1A mutations using a combination of the checkpoint and histone deacetylase inhibitors.<i>See related article by Fukumoto et al., p. 5482</i>.
|
31676676 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.
|
31731647 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that inhibition of HDAC6 synergizes with anti-PD-L1 immune checkpoint blockade in ARID1A-inactivated ovarian cancer.
|
31311810 |
2019 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results illustrated that ARID1A loss in ovarian cancer leads to MDR through upregulation of MRP2, providing an opportunity to overcome the ARID1A loss induced chemoresistance of ovarian cancer by targeting MRP2.
|
29660381 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of tumors with absent ARID1A were ovarian carcinomas, predominantly of clear cell or low-grade serous type.
|
29170871 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors formed by an ARID1A-deficient ovarian cancer cell line in syngeneic mice displayed increased mutation load, elevated numbers of tumor-infiltrating lymphocytes, and PD-L1 expression.
|
29736026 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity.
|
29669287 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that ARID1A mutation confers sensitivity to pan-HDAC inhibitors such as SAHA in ovarian cancers.
|
29590609 |
2018 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that HDAC6 activity is essential in ARID1A-mutated ovarian cancers.
|
28737768 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A key HDAC6 dependency of ARID1A-mutated ovarian cancer.
|
28752851 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis‑associated ovarian cancers and endometrial cancers.
|
26572704 |
2016 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of BAF250a (BRG-associated factor 250a)/ARIDIA (AT-rich interactive domain 1A) protein expression was identified among endometriosis-associated ovarian carcinomas and ovarian endometriosis, and this phenomenon was described as a possible early event in the transformation of endometriosis into cancer.
|
26832958 |
2016 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AT-rich interactive domain 1A gene (ARID1A) loss is a frequent event in endometriosis-associated ovarian carcinomas.
|
26378916 |
2015 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
AT-rich interactive domain-containing protein 1A (ARID1A), a chromatin remodeling gene recently discovered to be a tumor suppressor in ovarian cancers, has been found to be mutated at low frequencies in many other tumors including colorectal carcinoma (CRC).
|
25311944 |
2014 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
ARID1A has been identified as a novel tumor suppressor gene in ovarian cancer and subsequently in various other tumor types.
|
24382590 |
2014 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (IHC) for BAF250a expression was performed on 127 chemotherapy-naive ovarian carcinomas (33 CCC, 29 EC, and 65 high-grade serous ovarian carcinomas (HGSC)).
|
24559118 |
2014 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
|
24036443 |
2013 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
|
22193641 |
2012 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ARID1A mutations in endometriosis-associated ovarian carcinomas.
|
20942669 |
2010 |